Metamizol Teva

Metamizole sodium, the active ingredient in Metamizol Teva, is a pyrazolone analgesic presented as an oral tablet for oral use. It is employed to relieve moderate to severe pain and to reduce fever in adult patients.

GNH USA supplies Metamizol Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizol Teva acts on pain and temperature regulation pathways, providing relief in several clinical situations.

Pain: delivers effective analgesia for acute and postoperative pain Fever: lowers elevated body temperature in febrile states Post‑operative pain: helps control pain after surgical procedures

Metamizol Teva may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset - Dizziness: transient light‑headedness - Hypotension: occasional drop in blood pressure - Rash: skin redness or itching - Sweating: increased perspiration - Headache: mild to moderate pain in the head

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells - Anaphylaxis: life‑threatening allergic reaction - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic injury: abnormal liver function tests - Blood dyscrasias: aplastic anemia or thrombocytopenia

Before prescribing Metamizol Teva, clinicians should consider several safety measures.

Baseline blood count: obtain complete blood count prior to initiation Allergy assessment: avoid in patients with known hypersensitivity to pyrazolones Renal function: use cautiously in impaired kidney function Pregnancy and lactation: safety not established, weigh risks and benefits Medical supervision: monitor regularly for signs of agranulocytosis or severe reactions Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight

Metamizol Teva can influence the activity of other medicines, requiring attention to potential interactions.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding - Other myelotoxic agents (e.g., cyclophosphamide): heightened bone‑marrow suppression - Immunosuppressants (e.g., azathioprine): additive risk of blood dyscrasias

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible additive hypotensive effect - Diuretics: may enhance blood‑pressure lowering - Other analgesics/NSAIDs: increased gastrointestinal irritation - Alcohol: potentiates central nervous system depression